Show simple item record

dc.contributor.authorKingston, Nen_US
dc.contributor.authorThomas, Ien_US
dc.contributor.authorJohns, Len_US
dc.contributor.authorMoss, Sen_US
dc.contributor.authorGrp, TMen_US
dc.identifier.citationCANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 pp. 1132 - 1136en_US
dc.description.abstractThe UK Age Trial of mammographic screening from age 40 has reported a nonsignificant 17% reduction in breast cancer mortality calculated on an “ intention to treat” basis. High levels of ad hoc screening in the control arm could potentially have diluted the estimated effect. Objectives: To estimate the level of unscheduled mammography in the control arm of the UK Age Trial. Methods: Data were obtained from questionnaires sent to a random sample of 3,706 women at five centers in the control arm of this trial. Questions included in the Office for National Statistics Omnibus Surveys about the timing of and reasons for any breast screening provided comparable data. The overall response rate was 58.8%. Results: Overall, 24.9% (95% confidence interval, 23.0-26.8) of Age Trial controls responding reported ever having had a mammogram, 18.2% reported a mammogram for symptomatic reasons, and 8.4% reported unscheduled mammography. Overall, 4.0% and 1.8% of women reported symptomatic and unscheduled mammography, respectively, within the previous 12 months. Results from the Omnibus surveys were similar, 14.2% of women reported previous mammography for symptomatic reasons or follow-up after breast cancer and 6.8% reported unscheduled mammography. Conclusions: The level of contamination due to mammographic screening in the control arm of the Age Trial was low and will have had a minimal effect on the estimated reduction in mortality from breast cancer. Impact: Estimating the extent of screening in the control arm in randomized trials of screening is important to inform interpretation of the results. Cancer Epidemiol Biomarkers Prev; 19(4); 1132-6. (C) 2010 AACR.en_US
dc.format.extent1132 - 1136en_US
dc.titleAssessing the Amount of Unscheduled Screening (”Contamination”) in the Control Arm of the UK “Age” Trialen_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
pubs.notesaffiliation: Moss, S (Reprint Author), Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England. Kingston, Nicola; Thomas, Iyamide; Johns, Louise; Moss, Sue; Trial Management Grp, Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England. keywords-plus: PROSTATE-CANCER research-areas: Oncology; Public, Environmental & Occupational Health web-of-science-categories: Oncology; Public, Environmental & Occupational Health author-email: funding-acknowledgement: National Institute for Health Research [10/57/55]; Medical Research Council [G9000793, G9000793(59464)]; Cancer Research UK [A3390] number-of-cited-references: 6 times-cited: 2 usage-count-last-180-days: 0 usage-count-since-2013: 3 journal-iso: Cancer Epidemiol. Biomarkers Prev. doc-delivery-number: 607FL unique-id: ISI:000278484400034 oa: gold_or_bronze da: 2018-08-21en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH)
pubs.embargo.termsNot knownen_US
icr.researchteamCancer Screening Evaluation Unit (DoH)en_US
dc.contributor.icrauthorMoss, Susan Maryen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record